奥沙利铂联合卡培他滨二线治疗晚期胃癌临床疗效观察

Combination chemotherapy with oxaUplatin and capecitabine as a second line chemotherapy for 24 patients with advanced gastric cancer

目的观察奥沙利铂（L—OHP）联合卡培他滨（商品名：希罗达）二线治疗晚期胃癌的临床疗效和毒副作用。方法晚期复治性胃癌26例，L—OHP130mg／m^2，加入5％葡萄糖注射液500ml中静脉滴注2h，第1天；卡培他滨1000mg／m^2，2次／d口服，第1-14天；28d为1周期，连用2个周期后评价疗效。结果25例可评价疗效，完全缓解（CR）1例，部分缓解（PR）7例。稳定（SD）5例，进展（PD）12例，客观有效率32．0％，中位疾病进展时间为5-3个月（3-9个月），1年生存率29．5％。所有患者均可评价毒副反应，主要为骨髓抑制、消化道副反应和神经毒性，均为可逆性。结论L-OHP联合卡培他滨二线治疗晚期胃癌疗效肯定，毒副作用小，值得临床推广及进-步研究。

Objective To evaluate efficacy and toxicity reactions of oxaliplatin and capecitabine as a second line chemotherapy regimens for patients of advanced gastric cancer. Method 26 patients of advanced refractory gastric cancer, oxaliplatin was administered at a dose of 130 mg/m^2 with 500 ml of 5 % GS by drip infusion for 2 hours on day 1 and capecitabine 1000 mg/m^2 twice daily was adopted orally on day 1- 14. The chemotherapy was repeated every 28 days and the efficacy was evaluated after 2 cycles. Results Respons could he assessed in 25 patients, One patient achieved a complete response, seven had partial responses, five stable diseas and twelve progression, giving an overall response rate of 32 %. The median time to disease progression（TYP） was 5.3 months （3-19 months） and one-year rate was 29.5 %. Toxicity could be assessed in all patients and the principal adverse events were gastrointestinal,neural toxicity and myelosuppression and they are revesed. Conclusion Capecitabine in combination with oxaliplatin was effective and well tolerated second-line treatment in patients with advanced refractory gastric cancer. It deserves further clinical research.